Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

  • Group 1 is a control group of 40 subjects, 20 male and 20 female, dosed with vehicle once per day for 30 days. Of this group, 10 males and 10 females will be fed ad libitum, while the remainder will be subject to a restricted diet. Half of the subjects will be terminated after 30 days, while the other half will be subject to a 14-day recovery period; the subjects selected for recovery will be divided equally among animals fed ad libitum and those subject to restricted feeding (i.e., 5 males and 5 females with ad libitum feeding will move to recovery, and 5 males and 5 females with restricted diet will also move to recovery).
  • Group 2 is a low-dose group of 40 subjects, 20 male and 20 female, dosed at 5 mg/kg once per day for 30 days. Of this group, 10 males and 10 females will be fed ad libitum, while the remainder will be subject to a restricted diet. Three subjects of each sex and feeding pattern will be subject to blood sampling for the purpose of TK analysis (i.e., 3 males and 3 females from those fed ad libitum and 3 males and 3 females from those receiving a restricted diet)
  • Group 3 is a high-dose group of 40 subjects, 20 male and 20 female, dosed at 100 mg/kg once per day for 30 days. Of this group, 10 males and 10 females will be fed ad libitum, while the remainder will be subject to a restricted diet. Of those subjects fed ad libitum, 3 males and 3 females will be subject to blood sampling for the purpose of TK analysis and terminated on day 30; 3 males and 3 females (other than those selected for TK analysis) will be subject to a 14-day recovery period, and the remaining subjects will be terminated on day 30. of the subjects given a restricted diet, 6 males and 6 females will be subject to blood sampling for the purpose of TK analysis; half of these subjects will be terminated on day 30 while the others are subject to a 14-day recovery period before termination. The balance of the subjects receiving a restricted diet will be terminated at the end of the treatment dosing period (day 30).
Group
Number
Group LabelDose LevelNumber of Animals (Both Sexes Combined)
Fed Ad LibitumRestricted Feeding
Non-toxicokineticToxicokineticNon-toxicokineticToxicokinetic
NonrecoveryRecoveryNonrecoveryRecoveryNonrecoveryRecoveryNonrecoveryRecovery
1Group 1, ControlVehicle Control101000101000
2Group 2, 5 mg/kg5 mg/kg/day1406014060
3Group 3, 100 mg/kg100 mg/kg/day86608066

...

The variety of feeding and TK analysis factors do not affect the TE dataset, which deals only with treatmentsdosing. The fact that only some of the treatment dosing elements are combined with the recovery element is only captured in the TA dataset.

Dataset wrap
Namete

Jira
showSummaryfalse
serverIssue Tracker (JIRA)
serverId85506ce4-3cb3-3d91-85ee-f633aaaf4a45
keyTOBA-215

Dataset2
RowSTUDYIDDOMAINETCDELEMENTTESTRLTEENRLTEDUR
1TDM4TESCRNScreenStart of screening period7 days after start of ElementP7D
2TDM4TECONTROLControlAt completion of SCRN Element30 days after start of ElementP30D
3TDM4TET55 mg/kg Drug AAt completion of SCRN Element30 days after start of ElementP30D
4TDM4TET100100 mg/kg Drug AAt completion of SCRN Element30 days after start of ElementP30D
5TDM4TERECORecovery1 day after last dose with treatment product or vehicle control14 days after start of ElementP14D

...

Despite the complex description in the study protocol, there are only 5 trial arms in this study. All subjects experience a screening element. Based upon the result of randomization, they then receive 1 of 3 different treatmentsexposure levelsexp; some of the subjects receiving the vehicle control or the medium high dose are subject to a recovery period post-treatment.

Jira
showSummaryfalse
serverIssue Tracker (JIRA)
serverId85506ce4-3cb3-3d91-85ee-f633aaaf4a45
keyTOBA-660
exposure. This can be depicted as follows.

Dataset wrap
Nameta
Dataset2
RowSTUDYIDDOMAINARMCDARMTAETORDETCDELEMENTTABRANCHEPOCH
1TDM4TA1Control1SCRNScreenRandomized to Group 1PRE-TREATMENTEXPOSURE
2TDM4TA1Control2CONTROLControl
TREATMENTEXPOSURE
3TDM4TA1RControl + Recovery1SCRNScreenRandomized to Group 1 with RecoveryPRE-TREATMENTEXPOSURE
4TDM4TA1RControl + Recovery2CONTROLControl
TREATMENTEXPOSURE
5TDM4TA1RControl + Recovery3RECORecovery
RECOVERY
6TDM4TA2Low Dose1SCRNScreenRandomized to Group 2PRE-TREATMENTEXPOSURE
7TDM4TA2Low Dose2T55 mg/kg Drug A
TREATMENTEXPOSURE
8TDM4TA3High Dose1SCRNScreenRandomized to Group 3PRE-TREATMENTEXPOSURE
9TDM4TA3High Dose2T100100 mg/kg Drug A
TREATMENTEXPOSURE
10TDM4TA3RHigh Dose + Recovery1SCRNScreenRandomized to Group 3 with RecoveryPRE-TREATMENTEXPOSURE
11TDM4TA3RHigh Dose + Recovery2T100100 mg/kg Drug A
TREATMENTEXPOSURE
12TDM4TA3RHigh Dose + Recovery3RECORecovery
RECOVERY

...

In this study there are multiple experimental factors of interest: the treatment dosing level given during the treatment exposure epoch (3 levels), the feeding regimen of the subjects (ad libitum vs. restricted feeding), whether the subjects are to be used for TK analysis, and whether the subjects will be terminated at the end of the dosing period or experience a recovery period. The combination of these factors (3x2x2x2) could lead to up to 24 possible combinations or sets; however, upon careful reading of the description there are 14 sets that will actually be part of the study:

...